Targeting death and decoy receptors of the tumour-necrosis factor superfamily (original) (raw)

• O'Malley, W. E., Achinstein, B. & Shear, M. J. Action of bacterial polysaccharide on tumors II: damage of sarcoma 37 by serum of mice treated with Serratia marscescens polysaccharide and induced tolerance. J. Natl Cancer Inst. 29, 1169–1175 (1962).
  CAS Google Scholar
• Carswell, E. A. et al. An endotoxin-induced serum factor that causes necrosis of tumors. Proc. Natl Acad. Sci. USA 72, 3666–3670 (1975).
  Article CAS PubMed PubMed Central Google Scholar
• Helson, L., Green, S., Carswell, E. & Old, L. J. Effect of tumor necrosis factor on cultured melanoma cells. Nature 258, 731–732 (1975).
  Article CAS PubMed Google Scholar
• Pennica, D., Nedwin, G. E., Hayflick, J., Aggarwal, B. B. & Goeddel, D. V. Human tumor necrosis factor: precursor structure, expression and homology to lymphotoxin. Nature 312, 724–729 (1984).
  Article CAS PubMed Google Scholar
• Gray, P. W. et al. Cloning and expression of cDNA for human lymphotoxin, a lymphkine with tumor necrosis activity. Nature 312, 721–724 (1984).
  Article CAS PubMed Google Scholar
• Beutler, B. et al. Identity of tumor necrosis factor and the macrophage-secreted factor cachectin. Nature 316, 552–554 (1985).
  Article CAS PubMed Google Scholar
• Browning, J. L. et al. Lymphotoxin-β, a novel member of the TNF family that forms a heterotrimeric complex with lymphotoxin on the cell surface. Cell 72, 847–856 (1993).
  Article CAS PubMed Google Scholar
• Aggarwal, B. B., Eessalu, T. E. & Hass, P. E. Characterization of receptors for tumor necrosis factor and their regulation by γ-interferon. Nature 318, 665–667 (1985).
  Article CAS PubMed Google Scholar
• Stamenkovic, I., Clark, E. A. & Seed, B. A B-lymphocyte activation molecule related to the nerve growth factor receptor and induced by cytokines in carcinomas. EMBO J. 8, 1403–1410 (1989).
  Article CAS PubMed PubMed Central Google Scholar
• Kwon, B. S. & Weissman, S. M. cDNA sequences of two inducible T-cell genes. Proc. Natl Acad. Sci. USA 86, 1963–1967 (1989).
  Article CAS PubMed PubMed Central Google Scholar
• Johnson, D. et al. Expression and structure of the human NGF receptor. Cell 47, 545–554 (1986).
  Article CAS PubMed Google Scholar
• Tartaglia, L. & Goeddel, D. Two TNF receptors. Immunol. Today 13, 151–153 (1992).
  Article CAS PubMed Google Scholar
• Smith, C. A., Farrah, T. & Goodwin, R. G. The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death. Cell 76, 959–962 (1994).
  Article CAS PubMed Google Scholar
• Wiley, S. R. et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3, 673–682 (1995).
  Article CAS PubMed Google Scholar
• Pitti, R. M. et al. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor receptor family. J. Biol. Chem. 271, 12697–12690 (1996).References 14 and 15 provided the first identification and characterization of APO2L/TRAIL as an apoptosis-inducing ligand.
  Article Google Scholar
• Ashkenazi, A. & Dixit, V. M. Death receptors: signaling and modulation. Science 281, 1305–1308 (1998).
  Article CAS PubMed Google Scholar
• Wallach, D. Cytokine Reference:TNF Ligand and TNF/NGF Receptor Families (Academic, San Diego, 2000).
  Google Scholar
• Yan, M. et al. Identification of a novel receptor for B lymphocyte stimulator that is mutated in a mouse strain with severe B cell deficiency. Curr. Biol. 11, 1547–1552 (2001).
  Article CAS PubMed Google Scholar
• Thompson, J. S. et al. BAFF-R, a newly identified TNF receptor that specifically interacts with BAFF. Science 293, 2108–2111 (2001).
  Article CAS PubMed Google Scholar
• Wiley, S. R. et al. A novel TNF receptor family member binds TWEAK and is implicated in angiogenesis. Immunity 15, 837–846 (2001).
  Article CAS PubMed Google Scholar
• Locksley, R. M., Killeen, N. & Lenardo, M. J. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 104, 487–501 (2001).
  Article CAS PubMed Google Scholar
• Eck, M. J. & Sprang, S. R. The structure of tumor necrosis factor-α at 2.6Å resolution. J. Biol. Chem. 264, 17595–17605 (1989).
  Article CAS PubMed Google Scholar
• Eck, M. J., Ultsch, M., Rinderknecht, E., de Vos, A. M. & Sprang, S. R. The structure of human lymphotoxin (tumor-necrosis factor-β) at 1. 9Å resolution. J. Biol. Chem. 267, 2119–2122 (1992).
  Article CAS PubMed Google Scholar
• Hymowitz, S. G. et al. A unique zinc-binding site revealed by a high-resolution X-ray structure of homotrimeric Apo2L/TRAIL. Biochemistry 39, 633–640 (2000).
  Article CAS PubMed Google Scholar
• Karpusas, M. et al. 2Å crystal structure of an extracellular fragment of human CD40 ligand. Structure 3, 1031–1039 (1995).
  Article CAS PubMed Google Scholar
• Lam, J., Nelson, C. A., Ross, F. P., Teitelbaum, S. L. & Fremont, D. H. Crystal structure of the TRANCE/RANKL cytokine reveals determinants of receptor-ligand specificity. J. Clin. Invest. 108, 971–979 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• Idriss, H. T. & Naismith, J. H. TNF and the TNF receptor superfamily: structure-function relationship(s). Microsc. Res. Tech. 50, 184–195 (2000).
  Article CAS PubMed Google Scholar
• Chinnaiyan, A. M., O'Rourke, K., Tewari, M. & Dixit, V. M. FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell 81, 505–512 (1995).
  Article CAS PubMed Google Scholar
• Boldin, M. P. et al. A novel protein that interacts with the death domain of Fas/APO1 contains a sequence motif related to the death domain. J. Biol. Chem. 270, 387–391 (1995).
  Article CAS PubMed Google Scholar
• Hsu, H., Xiong, J. & Goeddel, D. The TNF receptor-associated protein TRADD signals cell death and NF-κB activation. Cell 81, 495–504 (1995).
  Article CAS PubMed Google Scholar
• Adams, J. & Cory, S. The Bcl-2 protein family: arbiters of cell survival. Science 281, 1322–1326 (1998).
  Article CAS PubMed Google Scholar
• Green, D. Apoptotic pathways: paper wraps stone blunts scissors. Cell 102, 1–4 (2000).
  Article CAS PubMed Google Scholar
• Hunt, A. & Evan, G. Till death us do part. Science 293, 1784–1785 (2001).
  Article CAS PubMed Google Scholar
• Du, C., Fang, M., Li, Y., Li, L. & Wang, X. Smac, a mitochondrial protein that promotes cytochrome _c_-dependent caspase activation by eliminating IAP inhibition. Cell 102, 33–42 (2000).
  Article CAS PubMed Google Scholar
• Verhagen, A. M. et al. Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to an antagonizing IAP protein. Cell 102, 43–53 (2000).
  Article CAS PubMed Google Scholar
• Wallach, D. et al. Tumor necrosis factor receptor and Fas signaling mechanisms. Annu. Rev. Immunol. 17, 331–367 (1999).
  Article CAS PubMed Google Scholar
• Simonet, W. S. et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89, 309–319 (1997).
  Article CAS PubMed Google Scholar
• Emery, J. G. et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J. Biol. Chem. 273, 14363–14367 (1998).
  Article CAS PubMed Google Scholar
• Pitti, R. et al. Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature 396, 699–703 (1998).Reports the first identification of DcR3 and shows its interaction with FASL and its overexpression in tumours.
  Article CAS PubMed Google Scholar
• Yu, K. et al. A newly identified member of tumor necrosis factor receptor superfamily (TR6) suppresses LIGHT-mediated apoptosis. J. Biol. Chem. 274, 13733–13736 (1999).
  Article CAS PubMed Google Scholar
• Migone, T.-S. et al. TL1A is a TNF-like ligand for DR3 and TR6/DcR3 and functions as a T cell costimulator. Immunity 16, 479–492 (2002).
  Article CAS PubMed Google Scholar
• Hersh, E. M. et al. Phase II studies of recombinant human tumor necrosis factor-α in patients with malignant disease: a summary of the Southwest Oncology Group experience. J. Immunother. 10, 426–431 (1991).
  Article CAS PubMed Google Scholar
• Eggermont, A. M. M. TNF registered in Europe: does TNF get a second chance? J. Immunother. 23, 505–506 (2000).
  Article CAS PubMed Google Scholar
• Alexander, H. R. J. The effects of limb perfusion with tumor necrosis factor on circulating levels of proinflammatory cytokines. J. Immunother. 24, 285–286 (2001).
  Article PubMed Google Scholar
• Wielockx, B. et al. Inhibition of matrix metalloproteinases blocks lethal hepatitis and apoptosis induced by tumor necrosis factor and allows safe antitumor therapy. Nature Med. 7, 1202–1208 (2001).Provides a potential approach to mitigating the systemic toxicity of TNF and improving its therapeutic index.
  Article CAS PubMed Google Scholar
• Stoelcker, B., Hehlgans, T., Bluethmann, H., Luther, T. & Mannel, D. N. Tumor necrosis factor induces tumor necrosis via tumor necrosis factor receptor type-1-expressing endothelial cells of the tumor vasculature. Am. J. Pathol. 156, 1171–1176 (2000).Shows that, in a mouse fibrosarcoma model, TNF exerts its tumour-necrotizing effect indirectly, by acting through TNFR1 on tumour endothelial cells.
  Article CAS PubMed PubMed Central Google Scholar
• Pan, G. et al. The receptor for the cytotoxic ligand TRAIL. Science 276, 111–113 (1997).
  Article CAS PubMed Google Scholar
• Sheridan, J. P. et al. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science 277, 818–821 (1997).
  Article CAS PubMed Google Scholar
• Pan, G. et al. An antagonist decoy receptor and a new death domain-containing receptor for TRAIL. Science 277, 815–818 (1997).
  Article CAS PubMed Google Scholar
• Walczak, H. et al. TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. EMBO J. 16, 5386–5397 (1997).
  Article CAS PubMed PubMed Central Google Scholar
• Marsters, S. A. et al. A novel receptor for Apo2L/TRAIL contains a truncated death domain. Curr. Biol. 7, 1003–1006 (1997).
  Article CAS PubMed Google Scholar
• Degli-Esposti, M. et al. Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family. J. Exp. Med. 186, 1165–1170 (1997).
  Article CAS PubMed PubMed Central Google Scholar
• Degli-Esposti, M. A. et al. The novel receptor TRAIL-R4 induces NF-κB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. Immunity 7, 813–820 (1997).
  Article CAS PubMed Google Scholar
• Truneh, A. et al. Temperature-sensitive differential affinity of TRAIL for its receptors. J. Biol. Chem. 275, 23319–23325 (2000).
  Article CAS PubMed Google Scholar
• Cretney, E. et al. Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice. J. Immunol. 168, 1356–1361 (2002).
  Article CAS PubMed Google Scholar
• Takeda, K. et al. Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development. J. Exp. Med. 195, 161–169 (2002).References 55 and 56 show that inhibition of APO2L/TRAIL by gene knockout or neutralizing antibody increases the incidence and metastasis of mutagen-induced tumours in mice, indicating that this ligand is involved in immune surveillance against tumours.
  Article CAS PubMed PubMed Central Google Scholar
• Johnsen, A. C. et al. Regulation of APO2 ligand/trail expression in NK cells — involvement in NK cell-mediated cytotoxicity. Cytokine 11, 664–672 (1999).
  Article CAS PubMed Google Scholar
• Kayagaki, N. et al. Expression and function of TNF-related apoptosis-inducing ligand on murine activated NK cells. J. Immunol. 163, 1906–1913 (1999).
  CAS PubMed Google Scholar
• Griffith, T. et al. Monocyte-mediated tumoricidal activity via the tumor necrosis factor-related cytokine, TRAIL. J. Exp. Med. 189, 1343–1353 (1999).
  Article CAS PubMed PubMed Central Google Scholar
• Kayagaki, N. et al. Involvement of TNF-related apoptosis-inducing ligand in human CD4+ T cell-mediated cytotoxicity. J. Immunol. 162, 2639–2647 (1999).
  CAS PubMed Google Scholar
• Mariani, S. & Krammer, P. Surface expression of TRAIL/Apo2 ligand in activated mouse T and B cells. Eur. J. Immunol. 28, 1492–1498 (1998).
  Article CAS PubMed Google Scholar
• Jeramias, I., Herr, I., Boehler, T. & Debatin, K. M. TRAIL/Apo-2-ligand-induced apoptosis in human T cells. Eur. J. Immunol. 28, 143–152 (1998).
  Article Google Scholar
• Thomas, W. D. & Hersey, P. TNF-related apoptosis-inducing ligand (TRAIL) induces apoptosis in Fas ligand-resistant melanoma cells and mediates CD4 T cell killing of target cells. J. Immunol. 161, 2195–2200 (1998).
  CAS PubMed Google Scholar
• Martinez-Lorenzo, M. J. et al. Involvement of Apo2 ligand/TRAIL in activation-induced death of Jurkat and human peripheral blood T cells. Eur. J. Immunol. 28, 2714–2725 (1998).
  Article CAS PubMed Google Scholar
• Kayagaki, N. et al. Type I interferons (IFNs) regulate tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression on human T cells: a novel mechanism for the antitumor effects of type I IFNs. J. Exp. Med. 189, 1451–1460 (1999).
  Article CAS PubMed PubMed Central Google Scholar
• Chen, Q. et al. Induction of Apo2L and modulation of Bcl-2-related proteins regulate Type I interferon-induced apoptosis in multiple myeloma. Blood 98, 2183–2192 (2001).
  Article CAS PubMed Google Scholar
• Altucci, L. et al. Retinoic acid-induced apoptosis in leukemia cells is mediated by paracrine action of tumor-selective death ligand TRAIL. Nature Med. 7, 680–686 (2001).
  Article CAS PubMed Google Scholar
• Gong, B. & Almasan, A. Genomic organization and transcriptional regulation of human Apo2L/TRAIL gene. Biochem. Biophys. Res. Commun. 278, 747–752 (2000).
  Article CAS PubMed Google Scholar
• Clarke, P. et al. Reovirus-induced apoptosis is mediated by TRAIL. J. Virol. 74, 8135–8139 (2000).
  Article CAS PubMed PubMed Central Google Scholar
• Secchiero, P. et al. Human herpesvirus 7 induces the functional upregulation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) coupled to TRAIL-R1 down-modulation in CD4+ T cells. Blood 15, 2474–2481 (2001).
  Article Google Scholar
• Sato, K. et al. Antiviral response by natural killer cells through TRAIL gene induction by IFN-α/β. Eur. J. Immunol. 31, 3138–3146 (2001).
  Article CAS PubMed Google Scholar
• Monleon, I. et al. Differential secretion of Fas ligand or APO2 ligand/TNF-related apoptosis-inducing ligand-carrying microvesicles during activation-induced death of human T cells. J. Immunol. 167, 6736–6744 (2001).
  Article CAS PubMed Google Scholar
• Mariani, S. & Krammer, P. Differential regulation of TRAIL and CD95 ligand in transformed cells of the T and B lymphocyte lineage. Eur. J. Immunol. 28, 973–982 (1998).
  Article CAS PubMed Google Scholar
• Hymowitz, S. G. et al. Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with death receptor 5. Molec. Cell 4, 563–571 (1999).
  Article CAS PubMed Google Scholar
• Bodmer, J.-L., Meier, P., Tschopp, J. & Schneider, P. Cysteine 230 is essential for the structure and activity of the cytotoxic ligand TRAIL. J. Biol. Chem. 275, 20632–20637 (2000).
  Article CAS PubMed Google Scholar
• Ashkenazi, A. et al. Safety and anti-tumor activity of recombinant soluble Apo2 ligand. J. Clin. Invest. 104, 155–162 (1999).
  Article CAS PubMed PubMed Central Google Scholar
• Walczak, H. et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nature Med. 5, 157–163 (1999).References 76 and 77 provided the first evidence that soluble APO2L/TRAIL proteins induce tumour-cell apoptosis in vivo . Reference 76 described the non-tagged, trimeric APO2L/TRAIL variant and showed its efficacy as a single agent and its synergy with chemotherapy against tumour xenografts. Reference 77 described a modified leucine-zipper-fused variant and showed its single-agent activity.
  Article CAS PubMed Google Scholar
• Rieger, J., Naumann, U., Glaser, T., Ashkenazi, A. & Weller, M. Apo2 ligand: a novel lethal weapon against malignant glioma? FEBS Lett. 427, 124–128 (1998).
  Article CAS PubMed Google Scholar
• Keane, M. M., Ettenberg, S. A., Nau, M. M., Russel, E. & Lipkowitz, S. Chemotherapy augments TRAIL-induced apoptosis in breast cell lines. Cancer Res. 59, 734–741 (1999).
  CAS PubMed Google Scholar
• Mizutani, Y., Yoshida, O., Miki, T. & Bonavida, B. Synergistic cytotoxicity and apoptosis by Apo-2 ligand and adriamycin against bladder cancer cells. Clin. Cancer Res. 5, 2605–2612 (1999).
  CAS PubMed Google Scholar
• Gazitt, Y. TRAIL is a potent inducer of apoptosis in myeloma cells derived from multiple myeloma patients and is not cytotoxic to hematopoietic stem cells. Leukemia 13, 1817–1824 (1999).
  Article CAS PubMed Google Scholar
• Yu, R., Mandlekar, S., Ruben, S., Ni, J. & Kong, A.-N. T. Tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in androgen-independent prostate cancer cells. Cancer Res. 60, 2384–2389 (2000).
  CAS PubMed Google Scholar
• Mitsiades, N., Poulaki, V., Mitsiades, C. & Tsokos, M. Ewing's sarcoma family tumors are sensitive to tumor necrosis factor-related apoptosis-inducing ligand and express death receptor 4 and death receptor 5xs. Cancer Res. 61, 2704–2712 (2001).
  CAS PubMed Google Scholar
• Ashkenazi, A. & Dixit, V. M. Apoptosis control by death and decoy receptors. Curr. Opin. Cell Biol. 11, 255–260 (1999).
  Article CAS PubMed Google Scholar
• Kelley, S. K. et al. Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy pharmacokinetics, and safety. J. Pharmacol. Exp. Ther. 299, 31–38 (2001).
  CAS PubMed Google Scholar
• Mitsiades, C. S. et al. TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications. Blood 98, 795–804 (2001).
  Article CAS PubMed Google Scholar
• Roth, W. et al. Locoregional Apo2L/TRAIL eradicates intracranial human malignant glioma xenografts in a thymic mice in the absence of neurotoxicity. Biochem. Biophys. Res. Commun. 265, 1999 (1999).
  Article CAS Google Scholar
• Pollack, I. F., Erff, M. & Ashkenazi, A. Direct stimulation of apoptotic signaling by soluble Apo2L/tumor necrosis factor-related apoptosis-inducing ligand leads to selective killing of glioma cells. Clin. Cancer Res. 7, 1362–1369 (2001).
  CAS PubMed Google Scholar
• Gliniak, B. & Le, T. Tumor necrosis factor-related apoptosis-inducing ligand's antitumor activity in vivo is enhanced by the chemotherapeutic agent CPT-11. Cancer Res. 59, 6153–6158 (1999).
  CAS PubMed Google Scholar
• Chinnaiyan, A. M. et al. Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy. Proc. Natl Acad. Sci. USA 97, 1754–1759 (2000).
  Article CAS PubMed PubMed Central Google Scholar
• Chuntharapai, A. et al. Isotype-dependent inhibition of tumor growth in vivo by monoclonal antibodies to death receptor 4. J. Immunol. 166, 4891–4898 (2001).
  Article CAS PubMed Google Scholar
• Ichikawa, K. et al. Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte toxicity. Nature Med. 7, 954–960 (2001).
  Article CAS PubMed Google Scholar
• Trauth, B. C. et al. Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science 245, 301–304 (1989).
  Article CAS PubMed Google Scholar
• Lawrence, D. et al. Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nature Med. 7, 383–385 (2001).
  Article CAS PubMed Google Scholar
• Jo, M. et al. Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nature Med. 6, 564–567 (2000).
  Article CAS PubMed Google Scholar
• Qin, J. Z., Chaturvedi, V., Bonish, B. & Nickoloff, B. J. Avoiding premature apoptosis of normal epidermal cells. Nature Med. 7, 385–386 (2001).References 94–96 together show that non-tagged, zinc-containing APO2L/TRAIL trimers have little toxicity towards cultured hepatocytes or keratinocytes, whereas tagged, non-optimized versions of the ligand induce apoptosis in these cell types.
  Article CAS PubMed Google Scholar
• Muhlenbeck, F. et al. The tumor necrosis factor-related apoptosis-inducing ligand receptors TRAIL-R1 and TRAIL-R2 have distinct cross-linking requirements for initiation of apoptosis and are non-redundant in JNK activation. J. Biol. Chem. 275, 32208–32213 (2000).
  Article CAS PubMed Google Scholar
• Evan, G. & Littlewood, T. A matter of life and cell death. Science 281, 1317–1322 (1998).
  Article CAS PubMed Google Scholar
• Mongkolsapaya, J. et al. Lymphocyte inhibitor of TRAIL: a new receptor protecting lymphocytes from the death ligand TRAIL. J. Immunol. 160, 3–6 (1998).
  CAS PubMed Google Scholar
• Zhang, X. D., Nguyen, T., Thomas, W. D., Sanders, J. E. & Hersey, P. Mechanisms of resistance of normal cells to TRAIL-induced apoptosis vary between different cell types. FEBS Lett. 482, 193–199 (2000).
  Article CAS PubMed Google Scholar
• Bernard, D., Quatannes, B., Vundenbunder, B. & Abbadie, C. Rel/NF-κB transcription factors protect against tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL)-induced apoptosis by up-regulating the TRAIL decoy receptor DcR1. J. Biol. Chem. 276, 27322–27328 (2001).
  Article CAS PubMed Google Scholar
• Kagawa, S. et al. Antitumor activity and bystander effects of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene. Cancer Res. 61, 3330–3338 (2001).
  CAS PubMed Google Scholar
• Bai, C. et al. Overexpression of M68/DcR3 in human gastrointestinal tract tumors independent of gene amplification and its location in a four-gene cluster. Proc. Natl Acad. Sci. USA 97, 1230–1235 (2000).
  Article CAS PubMed PubMed Central Google Scholar
• Oshima, K. et al. Amplification and expression of a decoy receptor for Fas ligand (DcR3) in virus (EBV or HTLV-1) associated lymphomas. Cancer Lett. 160, 89–97 (2000).
  Article Google Scholar
• Roth, W. et al. Soluble decoy receptor 3 is expressed by malignant gliomas and suppresses CD95 ligand-induced apoptosis and chemotaxis. Cancer Res. 61, 2759–2765 (2001).References 103–105 confirm and extend the observation that DcR3 is overexpressed in various tumours and that it acts as a decoy for FASL.
  CAS PubMed Google Scholar
• Nagata, S. Apoptosis by death factor. Cell 88, 355–365 (1997).
  Article CAS PubMed Google Scholar
• French, L. E. & Tschopp, J. Inhibition of death receptor signaling by FLICE-inhibitory protein as a mechanism for immune escape of tumors. J. Exp. Med. 190, 891–893 (1999).
  Article CAS PubMed PubMed Central Google Scholar
• Berke, G. The CTL's kiss of death. Cell Death Differ. 81, 9–12 (1995).
  CAS Google Scholar
• Medema, J., de Jong, J., van Hall, T., Melief, C. & Offringa, R. Immune escape of tumors in vivo by expression of cellular FLICE-inhibitory protein. J. Exp. Med. 190, 1033–1038 (1999).
  Article CAS PubMed PubMed Central Google Scholar
• Djerbi, M. et al. The inhibitor of death receptor signaling, FLICE-inhibitory protein defines a new class of tumor progression factors. J. Exp. Med. 190, 1025–1031 (1999).References 109 and 110 show that ectopic expression of FLIP, an intracellular inhibitor of death-receptor signalling, enables tumour cells to escape immune surveillance in mouse models. This is summarized in reference 107.
  Article CAS PubMed PubMed Central Google Scholar
• Alderson, M. R. et al. Fas transduces activation signals in normal human T lymphocytes. J. Exp. Med. 178, 2231–2235 (1993).
  Article CAS PubMed Google Scholar
• Tamada, K. et al. Modulation of T-cell-mediated immunity in tumor and graft-versus-host disease models through the LIGHT co-stimulatory pathway. Nature Med. 6, 283–289 (2000).
  Article CAS PubMed Google Scholar
• Roonie, I. A. et al. The lymphotoxin-β receptor is necessary and sufficient for LIGHT-mediated apoptosis of tumor cells. J. Biol. Chem. 275, 14307–14315 (2000).
  Article Google Scholar
• Li, H., Zhu, H., Xu, C.-J. & Yuan, J. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway to apoptosis. Cell 94, 491–501 (1998).
  Article CAS PubMed Google Scholar
• Luo, X., Budihardjo, I., Zou, H., Slaughter, C. & Wang, X. Bid, a Bcl2-interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 94, 481–490 (1998).
  Article CAS PubMed Google Scholar
• Gross, A. et al. Caspase cleaved Bid targets mitochondria and is required for cytochrome c release, while Bcl-xL prevents this release but not tumor necrosis factor-R1/Fas death. J. Biol. Chem. 274, 1156–1163 (1999).
  Article CAS PubMed Google Scholar
• Yin, X.-M. et al. Bid-deficient mice are resistant to Fas-induced hepatocellular apoptosis. Nature 400, 886–891 (1999).
  Article CAS PubMed Google Scholar
• Eskes, R., Desagher, S., Antonsson, B. & Martinou, J. Bid induces the oligomerization and insertion of Bax into the outer mitochondrial membrane. Mol. Cell. Biol. 20, 929–935 (2000).
  Article CAS PubMed PubMed Central Google Scholar
• Wei, M. et al. tBID, a membrane targeted death ligand, oligomerizes Bak to release cytochrome c. Genes Dev. 14, 2060–2071 (2000).
  Article CAS PubMed PubMed Central Google Scholar
• El-Deiry, W. S. Insights into cancer therapeutic design based on p53 and TRAIL receptor signaling. Cell Death Differ. 8, 1066–1075 (2001).
  Article CAS PubMed Google Scholar
• Scaffidi, C. et al. Differential modulation of apoptosis sensitivity in CD95 type I and type II cells. J. Biol. Chem. 274, 22532–22538 (1999).
  Article CAS PubMed Google Scholar
• Lindsten, T. et al. The combined functions of proapoptotic Bcl-2 family members Bak and Bax are essential for normal development of multiple tissues. Mol. Cell 6, 1389–1399 (2000).
  Article CAS PubMed PubMed Central Google Scholar
• Wei, M. C. et al. Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science 292, 727–730 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• Zhang, L., Yu, J., Park, B., Kinzler, K. & Vogelstein, B. Role of BAX in the apoptotic response to anticancer agents. Science 290, 989–992 (2000).
  Article CAS PubMed Google Scholar
• LeBlanc, H. et al. Tumor cell resistance to death receptor induced apoptosis through mutational inactivation of the proapoptotic Bcl2 homolog Bax. Nature Med. 8, 274–281 (2002).Shows that in DNA mismatch-repair-deficient tumour cells, Bax mutation can cause resistance to death-receptor ligands, including APO2L/TRAIL. It also shows that BAX-dependent resistance to this ligand can be circumvented by pre-exposure of the cells to chemotherapy, which upregulates DR5 and especially Bak expression.
  Article CAS PubMed Google Scholar
• Deng, Y., Lin, Y. & Wu, X. TRAIL-induced apoptosis requires Bax-dependent mitochondrial release of Smac/Diablo. Genes Dev. 16, 33–45 (2002).
  Article CAS PubMed PubMed Central Google Scholar
• Rampino, N. et al. Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype. Science 275, 967–969 (1997).
  Article CAS PubMed Google Scholar
• Banner, D. W. et al. Crystal structure of the soluble human 55 kD TNF receptor–human TNFβ complex: implications for TNF receptor activation. Cell 73 431–445 (1993).
  Article CAS PubMed Google Scholar
• Kischkel, F. C. et al. Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. EMBO J. 14, 5579–5588 (1995).
  Article CAS PubMed PubMed Central Google Scholar
• Kischkel, F. C. et al. Apo2L/TRAIL-dependent recruitment of endogenous FADD and caspase-8 to death receptors 4 and 5. Immunity 12, 611–620 (2000).
  Article CAS PubMed Google Scholar
• Sprick, M. R. et al. FADD/MORT1 and caspase-8 are recruited to TRAIL receptors 1 and 2 and are essential for apoptosis mediated by TRAIL receptor 2. Immunity 12, 599–609 (2000).
  Article CAS PubMed Google Scholar
• Bodmer, J. L. et al. TRAIL receptor-2 signals apoptosis through FADD and caspase-8. Nature Cell Biol. 2, 241–243 (2000).
  Article CAS PubMed Google Scholar
• Kischkel, F. C. et al. Death receptor recruitment of endogenous caspase-10 and apoptosis initiation in the absence of caspase-8. J. Biol. Chem. 276, 46639–46646 (2001).
  Article CAS PubMed Google Scholar
• Wang, J., Chun, H. J., Wong, W., Spencer, D. M. & Lenardo, M. J. Caspase-10 is an initiator caspase in death receptor signaling. Proc. Natl Acad. Sci. USA 98, 13884–13888 (2001).
  Article CAS PubMed PubMed Central Google Scholar
• Hsu, H., Shu, H. B., Pan, M. G. & Goeddel, D. V. TRADD–TRAF2 and TRADD–FADD interactions define two distinct TNF receptor 1 signal transduction pathways. Cell 84, 299–308 (1996).
  Article CAS PubMed Google Scholar
• Hsu, H., Huang, J., Shu, H., Baichwal, V. & Goeddel, D. TNF-dependent recruitment of the protein kinase RIP to the TNF receptor-1 signaling complex. Immunity 4, 387–396 (1996).
  Article CAS PubMed Google Scholar
• Chinnaiyan, A. M. et al. Signal transduction by DR3, a death domain-containing receptor related to TNFR-1 and CD95. Science 274, 990–992 (1996).
  Article CAS PubMed Google Scholar
• Marsters, S. et al. Apo3, a new member of the tumor necrosis factor receptor family, contains a death domain and activates apoptosis and NF-κB. Curr. Biol. 6, 1669–1676 (1996).
  Article CAS PubMed Google Scholar
• Kitson, J. et al. A death-domain-containing receptor that mediates apoptosis. Nature 384, 372–375 (1996).
  Article CAS PubMed Google Scholar
• Pan, G. et al. Identification and functional characterization of DR6, a novel death domain-containing TNF receptor. FEBS Lett. 431, 351–356 (1998).
  Article CAS PubMed Google Scholar
• Zhao, H. et al. Impaired c–Jun amino terminal kinase activity and T cell differentiation in death receptor 6–deficient mice.. J. Exp. Med. 194, 1441–1448 (2001).
  Article CAS PubMed PubMed Central Google Scholar